170886 ⎘
Detection or diagnosis of diseases Pediatrics
Sub-classes:CIRCULATING PROTEIN BIOMARKERS OF NECROTIZING ENTERROCOLITIS
#2PTX3 BIOMARKER FOR REDUCING ANTIBIOTIC TREATMENT IN NEWBORNS
#3METHODS AND COMPOSITIONS FOR ASSAYING BETA-HEXOSAMINIDASE ENZYMATIC ACTIVITY VIA MASS SPECTROMETRY
#4Diagnosis of Congenital Heart Block
#5METHODS, SYSTEMS AND COMPOSITIONS FOR THE PREDICTION AND PREVENTION OF PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS USING FECAL BIOMARKERS
#6BIOMARKERS OF METHOTREXATE-INDUCED IMMUNE TOLERANCE
#7Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
#8NOVEL ASSAY AND NOVEL METHODS OF TREATING HUTCHINSON-GILFORD PROGERIA SYNDROME
#9CELL-FREE DNA END CHARACTERISTICS
#10MARKER SET FOR EVALUATING THE DEVELOPMENT OF INFANT’S COMMUNICATION ABILITY AND USE THEREOF
#11PROTEOMIC SCREENING FOR LYSOSOMAL STORAGE DISEASES
#12Methods and Systems for Determining Autism Spectrum Disorder Risk
#13Methods and Systems for Determining Autism Spectrum Disorder Risk
#14FILTRATION-BASED METHODS FOR PREPARING FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING
#15ASSAYS AND METHODS FOR THE DIAGNOSIS OF POST-STREPTOCOCCAL DISORDERS
#16Systems and Methods for Dynamic Immunohistochemistry Profiling of Biological Disorders
#17FILTRATION-BASED METHODS FOR PREPARING FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING
#18INHIBITION OF AUTISM SPECTRUM DISORDER USING DECOY ANTIGENS TO MATERNAL BRAIN-REACTIVE ANTIBODIES
#19FILTRATION-BASED METHODS FOR PREPARING FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING
#20ANTIGENIC NEURON SPECIFIC ENOLASE PEPTIDES FOR DIAGNOSING AND TREATING AUTISM
#21Biomarkers for improving nutrion for infants at risk
#22REAGENT KIT FOR DETECTING SEX HORMONE AND METHOD FOR DETECTING SEX HORMONE USING SAME
#23Use of macimorelin in assessing growth hormone deficiency in children
#24Use of Lyso-GB1 as Druggable Target
#25Risk of allergy and nutrition to reduce that risk
#26Proteomic screening for lysosomal storage diseases
#27BIOMARKER FOR DIAGNOSING AUTISM SPECTRUM DISORDER
#28Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
#29Antibodies against HPA-1a
#30METHOD FOR MONITORING DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM
#31NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY SEVERITY DETERMINING METHOD AND PROGNOSIS PREDICTING METHOD
#32Biomarkers of methotrexate-induced immune tolerance
#33Inhibition of autism spectrum disorder using decoy antigens to maternal brain-reactive antibodies
#34Methods and compositions for screening and treating developmental disorders
#35CELL-FREE DNA END CHARACTERISTICS
#36Blood biomarkers for severe traumatic brain injuries
#37Methods and compositions for determining, and for minimizing, the likelihood of development of allergy in infants
#38Juvenile atopic dermatitis models
#39Use of lyso-Gb1 as druggable target
#40DIAGNOSTIC METHOD FOR PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME (PANS) AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCI INFECTION (PANDAS)
#41METHOD FOR MONITORING FETUS/PRETERM INFANT DEVELOPMENT, AND FOR PROMOTING THE NORMAL DEVELOPMENT OF PRETERM INFANTS
#42Risk of allergy and nutrition to reduce that risk
#43Method of detecting anti-Ri in a subject with a previous streptococcal infection
#44Inhibition of autism spectrum disorder using decoy antigens to maternal brain-reactive antibodies
#45Method to predict response to pharmacological chaperone treatment of diseases
#46Methods and systems for determining autism spectrum disorder risk
#47Agent for use in the case of fructose intolerance
#48SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR THE ORGANISM-SPECIFIC DIAGNOSIS OF SEPTICEMIA IN INFANTS
#49KITS FOR STRATIFYING SCOLIOTIC SUBJECTS
#50Detection and treatment of LRP4-associated neurotransmission disorders
#51Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis
#52Method for the diagnosis of disorders caused by fetal alcohol syndrome
#53Method of Assessing Infection Status
#54Infant formulas containing docosahexaenoic acid and lutein
#55Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (PANDAS)
#56Prophylaxis and treatment of preterm birth associated bronchopulmonary dysplasia (BPD)
#57Bile acid biomarkers for Niemann-Pick diseases, methods and uses therefor
#58EARLY PLACENTA INSULIN-LIKE PEPTIDE (PRO-EPIL)
#59Antibodies against HPA-1a
#60ASSAYS AND METHODS FOR THE DIAGNOSIS OF POST-STREPTOCOCCAL DISORDERS
#61METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES
#62Methods of diagnosing and treating neonatal reversion to fetal consciousness
#63Detection and treatment of LRP4-associated neurotransmission disorders
#64Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (PANDAS)
#65Electrified compositions for determining the risk of developing adolescent idiopathic scoliosis through the use of GI protein receptor
#66GI PROTEIN PHOSPHORYLATION AS MARKER FOR SCOLIOSIS AND SCOLIOSIS PROGRESSION, METHODS OF INCREASING GIPCR SIGNALING IN SCOLIOTIC SUBJECTS
#67BLOOD BASED METHODS OF ASSESSING ADOLESCENT DEPRESSION IN A SUBJECT
#68Methods and systems for determining autism spectrum disorder risk
#69Method to predict response to pharmacological chaperone treatment of diseases
#70METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK
#71Assay for measuring enzymatic modification of a substrate by a glycoprotein having enzymatic activity
#72Infant formulas containing docosahexaenoic acid and lutein
#73MATERIALS AND METHODS FOR DETECTING AND/OR PREDICTING NECROTIZING ENTEROCOLITIS IN INFANTS
#74Methods of enhancing genetic diagnosis
#75Diagnosis and treatment of neonatal encephalopathy
#76Methods of diagnosing and treating neonatal reversion to fetal consciousness
#77Method to predict response to pharmacological chaperone treatment of diseases
#78Methods and compositions for screening and treating developmental disorders
#79Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
#80Agent for use in the case of fructose intolerance
#81Genomic markers for prediction of long-term response to growth hormone (GH) therapy
#82Detection and treatment of LRP4-associated neurotransmission disorders
#83COMPOSITIONS AND METHODS FOR DETECTING NOONAN SYNDROME
#84METHODS FOR THE DIAGNOSIS, RISK ASSESSMENT, AND MONITORING OF AUTISM SPECTRUM DISORDERS
#85COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF MITOCHONDRIAL DISEASES
#86METHODS OF TREATING AUTISM AND AUTISM SPECTRUM DISORDERS
#87ENRICHMENT AND IDENTIFICATION OF FETAL CELLS IN MATERNAL BLOOD AND LIGANDS FOR SUCH USE
#88Infant formulas containing docosahexaenoic acid and lutein
#89Method to predict response to pharmacological chaperone treatment of diseases
#90METHODS FOR THE CLASSIFICATION AND DIAGNOSIS OF SCOLIOSIS THROUGH THE USE OF GI PROTEIN RECEPTOR
#91METHODS AND COMPOSITIONS FOR ALTERING BEHAVIOR ASSOCIATED WITH AUTISM SPECTRUM DISORDER
#92Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
#93Method for prenatal diagnosis
#94IMMUNODEFICIENCY SCREENING AT POINT OF CARE
#95Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
#96METHOD AND COMPOSITION FOR TREATING PATIENTS WITH A HIGH RISK OF DEVELOPING NEURO-IMMUNE DISORDERS OR DEVELOPMENTAL DELAYS, IDENTIFIED THROUGH THE UTILIZATION OF LOW HOMOCYSTEINE OR ITS PRECURSORS/METABOLITES, AS THE PREDICTOR OF SUCH RISK
#97BLOOD CELL SEPARATION
#98Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus-Noradrenergic system
#99Tandem mass spectrometry for detecting and/or screening for conditions associated with altered sterols
#100Blood Based Methods for Assessing Adolescent Depression in a Subject
#101Compositions and methods for detecting Noonan syndrome
#102Method for determination of inflammatory bowel disease
#103AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE
#104Methods for predicting embryo viability
#105RYR2 MUTATIONS
#106METHODS AND APPARATUS TO RECOGNIZE NERVE INJURIES
#107Method of determining potential susceptibility to development of ALTE and/or SIDS
#108REAGENT FOR DETERMINING LAMININ 5 ANTIGEN IN BIOLOGICAL SAMPLE AND ASSAY METHOD
#109Methods of treating autism and autism spectrum disorders
#110Method of reducing the risk of retinopathy of prematurity in preterm infants
#111Hypoxia inducible factor 2α for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
#112Method of using secretin and compositions made therefrom for the treatment of autism and other neurological, behavioral and immunological disorders
#113Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension